COVID Vaccines

FDA Deadline for Novavax’s COVID-19 Vaccine Passes Without Decision

A health official said delays stem from a desire to ensure safety.
FDA Deadline for Novavax’s COVID-19 Vaccine Passes Without Decision
A dose of Novavax's COVID-19 vaccine is prepared, in a file image. Joroen Jumelet/ANP/AFP via Getty Images
Zachary Stieber
Zachary Stieber
Senior Reporter
|Updated:
0:00
The Food and Drug Administration (FDA) missed a deadline for Novavax’s COVID-19 vaccine, just days after the agency’s top vaccine official announced his resignation.
The FDA was supposed to decide on Novavax’s application for a license for its COVID-19 shot by April 2, the Maryland-based company said in a statement.
Zachary Stieber
Zachary Stieber
Senior Reporter
Zachary Stieber is a senior reporter for The Epoch Times based in Maryland. He covers U.S. and world news. Contact Zachary at [email protected]
twitter
truth